allo HCT

PROCEDURE2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

HIVHematologic MalignanciesImmune System DiseasesLymphoproliferative DisordersPeripheral T-cell Lymphomas

Phase 1

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

RecruitingNCT05470491

National Cancer Institute (NCI)Hematologic Malignancies, HIV

Start: 2023-01-26End: 2027-07-30Target: 265Updated: 2026-04-01

Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

RecruitingNCT03922724

National Cancer Institute (NCI)Immune System Diseases, Lymphoproliferative Disorders, Peripheral T-cell Lymphomas

Start: 2019-04-18End: 2030-10-31Target: 330Updated: 2026-03-30

Related Papers

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Blood2024-11-05